📊 NVAX Key Takeaways
Is Novavax Inc. (NVAX) a Good Investment?
Novavax exhibits severe financial distress with negative stockholders' equity of -$144.8M and unsustainable negative free cash flow of -$98.5M annually. Flat revenue growth combined with persistent operating losses creates immediate solvency risk; at current burn rates, the $228.4M cash reserve will deplete within 2-3 years without fundamental operational improvement or capital restructuring.
Despite reporting strong operating and net margins with positive net income, revenue is flat year over year and cash generation is negative, suggesting weak earnings quality. Negative stockholders’ equity and liabilities exceeding assets present material balance sheet risk, even with adequate liquidity and high interest coverage. Until free cash flow turns sustainably positive and equity recovers, fundamentals skew unfavorably.
Novavax Inc. Key Strengths (NVAX)
- Maintains $228.4M cash reserve providing near-term operational runway
- Net loss improved significantly YoY (up 334.8%), indicating cost management progress
- Current ratio of 2.48x demonstrates adequate short-term liquidity position
- Strong operating and net margins
- High ROA and interest coverage with minimal long-term debt
- Solid liquidity with current and quick ratios above 2x
NVAX Stock Risks: Novavax Inc. Investment Risks
- Negative stockholders' equity of -$144.8M indicates technical balance-sheet insolvency
- Negative free cash flow of -$98.5M annually with unsustainable cash burn trajectory
- Zero YoY revenue growth ($139.5M flat) with no demonstrated market momentum or expansion capacity
- Negative operating cash flow of -$32.4M prevents debt service from core operations
- $291.0M long-term debt burden cannot be covered by operating income (interest coverage -4.1x)
- Negative stockholders’ equity despite reported profits
- Sustained negative operating and free cash flow (earnings quality risk)
- Flat revenue growth (0% YoY) undermines momentum
Key Metrics to Watch
- Operating cash flow reversal - must turn positive to validate sustainability
- Revenue growth acceleration - requires demonstrable market demand and product uptake
- Timeline to operating profitability - critical breakeven milestone needed
- Cash burn rate decline - monitor rate of cash depletion against reserve
- Debt restructuring or refinancing activity - viability of existing obligations
- Free cash flow and operating cash flow trend
- Stockholders’ equity trajectory back to positive
Novavax Inc. (NVAX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.48x current ratio provides a solid financial cushion.
NVAX Profit Margin, ROE & Profitability Analysis
NVAX vs Healthcare Sector: How Novavax Inc. Compares
How Novavax Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Novavax Inc. Stock Overvalued? NVAX Valuation Analysis 2026
Based on fundamental analysis, Novavax Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Novavax Inc. Balance Sheet: NVAX Debt, Cash & Liquidity
NVAX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Novavax Inc.'s revenue has declined by 43% over the 5-year period, indicating business contraction. The most recent EPS of $-5.41 indicates the company is currently unprofitable.
NVAX Revenue Growth, EPS Growth & YoY Performance
NVAX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $139.5M | -$9.5M | $-0.06 |
| Q3 2025 | $70.4M | -$106.5M | $-0.71 |
| Q2 2025 | $239.2M | $14.8M | $0.10 |
| Q1 2025 | $93.9M | -$147.6M | $-1.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Novavax Inc. Dividends, Buybacks & Capital Allocation
NVAX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Novavax Inc. (CIK: 0001000694)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NVAX
What is the AI rating for NVAX?
Novavax Inc. (NVAX) has a Combined AI Grade of C from Claude (D) and ChatGPT (C) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NVAX's key strengths?
Claude: Maintains $228.4M cash reserve providing near-term operational runway. Net loss improved significantly YoY (up 334.8%), indicating cost management progress. ChatGPT: Strong operating and net margins. High ROA and interest coverage with minimal long-term debt.
What are the risks of investing in NVAX?
Claude: Negative stockholders' equity of -$144.8M indicates technical balance-sheet insolvency. Negative free cash flow of -$98.5M annually with unsustainable cash burn trajectory. ChatGPT: Negative stockholders’ equity despite reported profits. Sustained negative operating and free cash flow (earnings quality risk).
What is NVAX's revenue and growth?
Novavax Inc. reported revenue of $139.5M.
Does NVAX pay dividends?
Novavax Inc. does not currently pay dividends.
Where can I find NVAX SEC filings?
Official SEC filings for Novavax Inc. (CIK: 0001000694) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NVAX's EPS?
Novavax Inc. has a diluted EPS of $-0.06.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NVAX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Novavax Inc. has a C grade with 80% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is NVAX stock overvalued or undervalued?
Valuation metrics for NVAX: ROE of N/A (sector avg: 15%), net margin of -6.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NVAX's AI grade for 2026?
Our dual AI analysis gives Novavax Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NVAX's free cash flow?
Novavax Inc.'s operating cash flow is $-32.4M, with capital expenditures of $66.0M. FCF margin is -70.6%.
How does NVAX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -6.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 2.48 (avg: 2).